Metabolic and toxicological considerations of newly approved prostate cancer drugs.

about

Is prostate cancer changing?: evolving patterns of metastatic castration-resistant prostate cancer.A case report of enzalutamide administration in a dialysis-dependent patient with castration-resistant prostate cancer.

P2860

Q39115673-D7EBB2F4-A511-476B-BB53-60163BB270FE Q53534465-B0B78B7A-68BF-4C15-A00A-E84C72FC6B44

P2860

Metabolic and toxicological considerations of newly approved prostate cancer drugs.

Item

http://www.wikidata.org/entity/Q38098596

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Metabolic and toxicological considerations of newly approved prostate cancer drugs.

@en

type

Item

label

Metabolic and toxicological considerations of newly approved prostate cancer drugs.

@en

prefLabel

Metabolic and toxicological considerations of newly approved prostate cancer drugs.

@en

P1476

Metabolic and toxicological considerations of newly approved prostate cancer drugs.

@en

P2093

Bobby Liaw

http://www.w3.org/2001/XMLSchema#string

Che-Kai Tsao

http://www.w3.org/2001/XMLSchema#string

Matthew D Galsky

http://www.w3.org/2001/XMLSchema#string

Tiffany Yee

http://www.w3.org/2001/XMLSchema#string

P2860

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

Identification of a novel cell type in peripheral lymphoid organs of mice. I. Morphology, quantitation, tissue distribution

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

Microtubules as a target for anticancer drugs

Increased survival with enzalutamide in prostate cancer after chemotherapy

Abiraterone and increased survival in metastatic prostate cancer

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomis

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer.

P304

835-846

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/17425255.2013.789019

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

William K. Oh

P577

2013-04-12T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23581700

http://www.w3.org/2001/XMLSchema#string

Metabolic and toxicological considerations of newly approved prostate cancer drugs.

about

P2860

P2860

Metabolic and toxicological considerations of newly approved prostate cancer drugs.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P698